{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:07:55Z","timestamp":1793048875456,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974444"],"award-info":[{"award-number":["81974444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jare.2025.11.038","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:53:09Z","timestamp":1763632389000},"page":"363-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Shanshan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jare.2025.11.038_b0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jare.2025.11.038_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jare.2025.11.038_b0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.jare.2025.11.038_b0025","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann. Oncol."},{"issue":"25","key":"10.1016\/j.jare.2025.11.038_b0030","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.jare.2025.11.038_b0040","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jare.2025.11.038_b0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nrm3982","article-title":"The unravelling of the ubiquitin system","volume":"16","author":"Ciechanover","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.jare.2025.11.038_b0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","article-title":"The ubiquitin-proteasome system in breast cancer","volume":"29","author":"Han","year":"2023","journal-title":"Trends Mol. Med."},{"issue":"9","key":"10.1016\/j.jare.2025.11.038_b0055","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.drudis.2022.06.009","article-title":"Deubiquitinating enzymes: promising targets for drug resistance","volume":"27","author":"Ge","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.jare.2025.11.038_b0060","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1878-0261.13149","article-title":"Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors","volume":"16","author":"Cheng","year":"2022","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.jare.2025.11.038_b0065","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41419-019-1628-8","article-title":"A novel UCHL(3) inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair","volume":"10","author":"Song","year":"2019","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0070","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41467-019-09232-8","article-title":"The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors","volume":"10","author":"Peng","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.jare.2025.11.038_b0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s43018-023-00535-w","article-title":"Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer","volume":"4","author":"Sun","year":"2023","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molcel.2018.02.023","article-title":"Discovery and characterization of ZUFSP\/ZUP1, a distinct deubiquitinase class important for genome stability","volume":"70","author":"Kwasna","year":"2018","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.molcel.2018.02.024","article-title":"ZUFSP deubiquitylates K63-linked polyubiquitin chains to promote genome stability","volume":"70","author":"Haahr","year":"2018","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41467-018-03148-5","article-title":"A family of unconventional deubiquitinases with modular chain specificity determinants","volume":"9","author":"Hermanns","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.jare.2025.11.038_b0095","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.celrep.2020.01.052","article-title":"Cooperation of the ATM and Fanconi Anemia\/BRCA pathways in double-strand break end resection","volume":"30","author":"Cai","year":"2020","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.jare.2025.11.038_b0100","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nmeth.2603","article-title":"Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome","volume":"10","author":"Zhang","year":"2013","journal-title":"Nat. Methods"},{"issue":"16","key":"10.1016\/j.jare.2025.11.038_b0105","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1093\/nar\/gkz545","article-title":"MORC2 regulates DNA damage response through a PARP1-dependent pathway","volume":"47","author":"Zhang","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.jare.2025.11.038_b0110","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41419-023-05900-2","article-title":"Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.jare.2025.11.038_b0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","article-title":"The DNA damage response: ten years after","volume":"28","author":"Harper","year":"2007","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.jare.2025.11.038_b0120","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.cell.2015.11.028","article-title":"Celebrating DNA's repair crew","volume":"163","author":"Kunkel","year":"2015","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.jare.2025.11.038_b0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrg2380","article-title":"Single-strand break repair and genetic disease","volume":"9","author":"Caldecott","year":"2008","journal-title":"Nat. Rev. Genet."},{"issue":"15","key":"10.1016\/j.jare.2025.11.038_b0130","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1128\/MCB.02248-06","article-title":"Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase","volume":"27","author":"Fisher","year":"2007","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.jare.2025.11.038_b0135","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.jare.2025.11.038_b0140","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1093\/nar\/gkv1476","article-title":"Single molecule detection of PARP1 and PARP2 interaction with DNA strand breaks and their poly(ADP-ribosyl)ation using high-resolution AFM imaging","volume":"44","author":"Sukhanova","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jare.2025.11.038_b0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2199-8-29","article-title":"Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition","volume":"8","author":"Aguilar-Quesada","year":"2007","journal-title":"BMC Mol. Biol."},{"issue":"2","key":"10.1016\/j.jare.2025.11.038_b0150","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1074\/jbc.M706734200","article-title":"PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites","volume":"283","author":"Haince","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.jare.2025.11.038_b0155","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-024-01832-1","article-title":"PARP1-DNA co-condensation: the driver of broken DNA repair","volume":"9","author":"Wei","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jare.2025.11.038_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111819","article-title":"MAVS promotes interferon signaling in RNA virus infection by ZUFSP-mediated chromatin regulation","volume":"131","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.jare.2025.11.038_b0170","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.molcel.2018.06.020","article-title":"Functions of FACT in breaking the nucleosome and maintaining its integrity at the single-nucleosome level","volume":"71","author":"Chen","year":"2018","journal-title":"Mol. Cell"},{"issue":"21","key":"10.1016\/j.jare.2025.11.038_b0175","doi-asserted-by":"crossref","first-page":"11929","DOI":"10.1093\/nar\/gkaa912","article-title":"The role of FACT in managing chromatin:disruption, assembly, or repair?","volume":"48","author":"Formosa","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.jare.2025.11.038_b0180","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/nar\/gkl241","article-title":"Modulation of nucleosome-binding activity of FACT by poly(ADP-ribosyl)ation","volume":"34","author":"Huang","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molcel.2008.02.029","article-title":"FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16","volume":"30","author":"Heo","year":"2008","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.jare.2025.11.038_b0190","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/0008-5472.CAN-16-3128","article-title":"SSRP1 cooperates with PARP and XRCC1 to facilitate single-strand DNA break repair by chromatin priming","volume":"77","author":"Gao","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jare.2025.11.038_b0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2021.07.020","article-title":"Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation","volume":"520","author":"Song","year":"2021","journal-title":"Cancer Lett."},{"issue":"8007","key":"10.1016\/j.jare.2025.11.038_b0200","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jare.2025.11.038_b0205","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jare.2025.11.038_b0210","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mco2.103","article-title":"Targeting DNA repair pathway in cancer: mechanisms and clinical application","volume":"2","author":"Wang","year":"2021","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.jare.2025.11.038_b0215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.029","article-title":"ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer","volume":"516","author":"Nam","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.jare.2025.11.038_b0220","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jare.2025.11.038_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.514313","article-title":"Identification of theaflavin-3,3'-digallate as a novel Zika Virus protease inhibitor","volume":"11","author":"Cui","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.jare.2025.11.038_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/nu14071391","article-title":"The prevention role of theaflavin-3,3'-digallate in angiotensin II induced pathological cardiac hypertrophy via CaN-NFAT signal pathway","volume":"14","author":"Zhou","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jare.2025.11.038_b0235","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2016.11.027","article-title":"In vitro and in vivo anti-inflammatory effects of theaflavin-3,3'-digallate on lipopolysaccharide-induced inflammation","volume":"794","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jare.2025.11.038_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175332","article-title":"Anti-inflammatory effects of theaflavin-3'-gallate during influenza virus infection through regulating the TLR4\/MAPK\/p38 pathway","volume":"938","author":"Sima","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.jare.2025.11.038_b0245","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1039\/D1FO04198C","article-title":"Theaflavin-3,3'-di-gallate represses prostate cancer by activating the PKC\u03b4\/aSMase signaling pathway through a 67 kDa laminin receptor","volume":"13","author":"Sun","year":"2022","journal-title":"Food Funct."},{"key":"10.1016\/j.jare.2025.11.038_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jff.2018.09.021","article-title":"Theaflavin-3, 3'-digallate inhibits ovarian cancer stem cells via suppressing Wnt\/\u03b2-Catenin signaling pathway","volume":"50","author":"Pan","year":"2018","journal-title":"J. Funct. Foods"},{"issue":"12","key":"10.1016\/j.jare.2025.11.038_b0255","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s42255-021-00491-8","article-title":"The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice","volume":"3","author":"Xu","year":"2021","journal-title":"Nat Metab"},{"issue":"22","key":"10.1016\/j.jare.2025.11.038_b0260","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1080\/14786419.2018.1557173","article-title":"A comparative anticancer study on procyanidin C1 against receptor positive and receptor negative breast cancer","volume":"34","author":"Koteswari","year":"2020","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.jare.2025.11.038_b0265","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jare.2023.07.007","article-title":"Procyanidin C1 inhibits tumor growth and metastasis in colon cancer via modulating miR-501-3p\/HIGD1A axis","volume":"60","author":"Lv","year":"2024","journal-title":"J. Adv. Res."},{"issue":"11","key":"10.1016\/j.jare.2025.11.038_b0270","doi-asserted-by":"crossref","first-page":"e1481","DOI":"10.1002\/ctm2.1481","article-title":"H. pylori-induced NF-\u03baB-PIEZO1-YAP1-CTGF axis drives gastric cancer progression and cancer-associated fibroblast-mediated tumour microenvironment remodelling","volume":"13","author":"Chen","year":"2023","journal-title":"Clin. Transl. Med."}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225009348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225009348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:48:54Z","timestamp":1789084134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225009348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":54,"alternative-id":["S2090123225009348"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.11.038","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}